Organic Letters
Letter
2
691−2694. (b) Juge,
Nabil, M.; Verbist, J. F.; Petit, J. Y. Toxicon 2001, 39, 1231−1237.
2) (a) For a review, see: Weinreb, S. M. Chem. Rev. 2006, 106,
́
M.; Grimaud, N.; Biard, J. F.; Sauviat, M. P.;
(
2
2
531−2549. (b) Abe, H.; Aoyagi, S.; Kibayashi, C. J. Am. Chem. Soc.
000, 122, 4583−4592. (c) Sun, P.; Sun, C.; Weinreb, S. M. J. Org.
Chem. 2002, 67, 4337−4345.
(
3) (a) Greshock, T. J.; Funk, R. L. Org. Lett. 2001, 3, 3511−3514.
(
b) Liu, J.; Hsung, R. P.; Peters, S. D. Org. Lett. 2004, 6, 3989−3992.
(
c) Abe, H.; Aoyagi, S.; Kibayashi, C. J. Am. Chem. Soc. 2005, 127,
1
473−1480. (d) Lee, M.; Lee, T.; Kim, E.-Y.; Ko, H.; Kim, D.; Kim, S.
, P.; Renaud, P. Org. Lett. 2006,
, 1569−1571. (f) Caldwell, J. J.; Craig, D. Angew. Chem., Int. Ed. 2007,
6, 2631−2634. (g) Fujitani, M.; Tsuchiya, M.; Okano, K.; Takasu, K.;
Org. Lett. 2006, 8, 745−748. (e) Schar
8
4
̈
Ihara, M.; Tokuyama, H. Synlett 2010, 2010, 822−826. (h) Meyer, A.
M.; Katz, C. E.; Li, S.-W.; Velde, D. V.; Aube, J. Org. Lett. 2010, 12,
244−1247. (i) Mei, S.-L.; Zhao, G. Eur. J. Org. Chem. 2010, 2010,
́
1
1
660−1668. (j) Perry, M. A.; Morin, M. D.; Slafer, B. W.; Rychnovsky,
S. D. J. Org. Chem. 2012, 77, 3390−3400. (k) In, J.; Lee, S.; Kwon, Y.;
Kim, S. Chem. - Eur. J. 2014, 20, 17433−17442. (l) Pandey, G.;
Janakiram, V. Chem. - Eur. J. 2015, 21, 13120−13126.
(
́
4) Sauviat, M.-P.; Vercauteren, J.; Grimaud, N.; Juge, M.; Nabil, M.;
Petit, J.-Y.; Biard, J.-F. J. Nat. Prod. 2006, 69, 558−562.
(
(
5) Li, C. P.; Blackman, A. J. Aust. J. Chem. 1995, 48, 955−965.
6) Issa, H. H.; Tanaka, J.; Rachmat, R.; Setiawan, A.; Trianto, A.;
Higa, T. Mar. Drugs 2005, 3, 78−83.
7) Sakamoto, K.; Tsujii, E.; Abe, F.; Nakanishi, T.; Yamashita, M.;
Shigematsu, N.; Izumi, S.; Okuhara, M. J. Antibiot. 1996, 49, 37−44.
8) Kam, T. S.; Lim, K. H. In The Alkaloids; Cordell, G. A., Ed.;
Academic Press: Amsterdam, 2008; Vol. 66, pp 1−111.
9) (a) Ferrier, R. J. J. Chem. Soc., Perkin Trans. 1 1979, 1455−1458.
b) Chida, N.; Ohtsuka, M.; Ogura, K.; Ogawa, S. Bull. Chem. Soc. Jpn.
991, 64, 2118−2121.
10) (a) For a review, see: Gorin, D. J.; Toste, F. D. Nature 2007,
46, 395−403. (b) Liu, Y.; Liu, M.; Guo, S.; Tu, H.; Zhou, Y.; Gao, H.
Org. Lett. 2006, 8, 3445−3448.
11) Mezailles, N.; Ricard, L.; Gagosz, F. Org. Lett. 2005, 7, 4133−
136.
12) For a similar catalysis with gold(I) catalysts, see: (a) Zi, W.;
(
(
(
(
1
(
4
(
́
4
(
Toste, F. D. J. Am. Chem. Soc. 2013, 135, 12600−12603. (b) Kim, H.;
Rhee, Y. H. J. Am. Chem. Soc. 2012, 134, 4011−4014.
(
13) For a review, see: Nishizawa, M.; Imagawa, H.; Yamamoto, H.
Org. Biomol. Chem. 2010, 8, 511−521.
14) Prevost, M.; St-Jean, O.; Guindon, Y. J. Am. Chem. Soc. 2010,
32, 12433−12439.
15) Clark, R. C.; Lee, S. Y.; Boger, D. L. J. Am. Chem. Soc. 2008, 130,
2355−12369.
16) Katoh, T.; Nagata, Y.; Kobayashi, Y.; Arai, K.; Minami, J.;
(
́
1
(
1
(
Terashima, S. Tetrahedron 1994, 50, 6221−6238.
(17) BouzBouz, S.; Cossy, J. Org. Lett. 2004, 6, 3469−3472.
(18) Molander, G. A.; Hahn, G. J. Org. Chem. 1986, 51, 1135−1138.
(
20) Although the stereochemistry of the spiro ring system and the
face selectivity of the protonation step in intermediate a have been
unknown, we think that the intermediate b can have both R and S
configurations of the C−Hg bond via the enolate form c.
(
21) House, H. O.; Auerbach, R. A.; Gall, M.; Peet, N. P. J. Org.
Chem. 1973, 38, 514−522.
22) Like the transition state f, transition states with the bulky
(
TBSO-containing alkyl group in an axial position in e, g, and h should
also be disfavored due to steric hindrance.
(
1
(
23) Barton, D. H. R.; McCombie, S. W. J. Chem. Soc., Perkin Trans. 1
975, 1574−1585.
24) In this ketone reduction, an equatorial hydride attack could
1
predominate as a result of avoiding the axial alkyl group. In the H
NMR spectrum of a major rotamer of 17, the coupling pattern of C9−
H at 4.12 ppm was observed as a doublet with J = 2.2 Hz showing an
equatorial proton.
D
Org. Lett. XXXX, XXX, XXX−XXX